HER2-targeted therapies have been widely available in the United Kingdom since 2006.4 ER− tumours are rarer, have an earlier age of onset and worse prognosis than ER+ tumours, in part because fewer targeted treatments are available than for ER+ tumours. Here, ERBB2 is linked to neoplasm.